20/20 HealthCare Partners LLC — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Verseau Therapeuticsverseautx.comMar 2017
Verseau develops cancer immunotherapies based on macrophage repolarization, converting immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages to trigger an immune response against tumors.
BiotechHealthtechAuburndale, US
Walter Capone(Executive Officer)Christine Bunt(Executive Officer, Director)Daniel Anderson(Executive Officer, Director, Promoter)
BoardRobert Langer(Director, Promoter)Jong Chang(Director)
PartnerHillel Bachrach· led
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.